Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras MAP17 y D-AKAP-2 en ratones db/db y organoides renales humanos.

IP: Maria Jose Soler Romeo
Collaborators: Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Juan Carlos León Román
Funding agency: Instituto de Salud Carlos III
Funding: 122210
Reference: PI21/01292
Duration: 01/01/2022 - 30/06/2026

RICORS2040 - Inflamación e inmunopatología de órganos y sistemas

IP: Maria Jose Soler Romeo
Collaborators: Francesc Moreso Mateos, Oriol Bestard Matamoros, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Maria Antonia Emilia Meneghini
Funding agency: Instituto de Salud Carlos III
Funding: 105765
Reference: RD21/0005/0016
Duration: 01/01/2022 - 31/12/2024

Caracterización molecular de Apolipoproteína A-Ib (ApoA-Ib): resolviendo el enigma del síndrome nefrótico idiopático.

IP: Concepció Jacobs Cachá
Collaborators: -
Funding agency: Fundación Renal Iñigo Alvarez de Toledo
Funding: 6000
Reference: FRIAT/PREMIS/2020/JACOBS
Duration: 22/09/2020 - 22/09/2020

Role of Apolipoprotein A-Ib in the idiopathic nephrotic syndrome

IP: Concepció Jacobs Cachá
Collaborators: -
Funding agency: Fundació La Marató de TV3
Funding: 199966.31
Reference: 202017/10
Duration: 30/03/2021 - 31/12/2024

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Janna Anthonina Slabbekoorn

Janna Anthonina Slabbekoorn

Tècnic/a Grau Superior
International Unit
Competitive Research Directorate
Read more
Maria Francesca Cortese

Maria Francesca Cortese

Main researcher
Microbiology
Read more
Maria Lopez Mendoza

Maria Lopez Mendoza

Predoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Clara Palmada Ibars

Clara Palmada Ibars

Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.